Ginkgo Bioworks Stock
Custom Microbes Design
Sign up today and learn more about Ginkgo Bioworks Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Ginkgo Bioworks Stock
Ginkgo Bioworks is a biotech company that designs custom microbes. The company creates custom microbes for three main areas: cultured ingredients, strain improvement, and enzymes. For cultured ingredients, Ginkgo Bioworks creates engineered yeasts to produce ingredients via fermentation for perfumes, foods, cosmetics, etc. For strain improvement, Ginkgo Bioworks engineers in-use organisms to improve efficiency and sustainability. For enzymes, Ginkgo Bioworks aims to discover "better" enzymes for various applications, such as cheesemaking and pharmaceuticals.
Ginkgo Bioworks' platform consists of its Foundries and Codebase. Foundries are Ginkgo Bioworks way to automate organism design and Codebase is Ginkgo Bioworks' library of cell, enzyme and genetic programs that help jumpstart new programs and discoveries.
Ginkgo Bioworks was founded in 2009. The company is based in Boston, Massachusetts.
Investors
Allen & Company
Stripe, Relativity Space, Vroom, Joby Aviation, Convoy, Blend, Aspiration, Freenome, Bolt Threads, Turo
Cascade Investment
Convoy, Delos, Schrodinger, OANDA Corporation, Ginkgo Bioworks
General Atlantic
AppDynamics, Toutiao, Chime, Wish, Avant, Articulate, Bolt Financial, Automation Anywhere, Coalition, Blend
Senator Investment Group
Relativity Space, Commonwealth Fusion, Ginkgo Bioworks, Animoca Brands
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Viking Global Investors
Impossible Foods, Moderna Therapeutics, Apeel Sciences, Adaptive Biotechnologies, Arctic Wolf, Talkdesk, Druva, Color, Clip, Iterable
Funding History
| July 2015 | $20K |
|---|---|
| June 2016 | $37K |
| October 2017 | $109K |
| September 2019 | $232K |
Management
Chief Executive Officer
Jason Kelly
Co-Founder
Barry Canton
Co-Founder
Austin Che
Co-Founder
Tom Knight
Co-Founder
Reshma Shetty
Press
endpts - Sep, 10 2020
Exclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibodyTechCrunch - Aug, 26 2020
Synthetic biology startups are giving investors an appetitefinsmes - May, 28 2020
Ginkgo Receives $70M InvestmentWall Streets Journal - Apr, 30 2020
Ginkgo Bioworks Redirects Its Biotech Platform to CoronavirusPR Newswire - Apr, 15 2020
Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 ResponseForbes - Mar, 20 2020
Synthetic Biology Powerhouse Ginkgo Bioworks Pledges $25 Million In Resources To Projects That Combat CoronavirusForbes - Jan, 21 2020
An Interview with Ginkgo’s Reshma Shetty On Co-Founding Synthetic Biology’s First UnicornYahoo Finance! - Jan, 13 2020
Ginkgo Bioworks CEO to Present at the 38th Annual J.P. Morgan Healthcare Conferencebusinessinsider - Oct, 9 2019
Gingko Bioworks raises $350 million fund for biotech spinoutsForbes - Aug, 5 2019
The Life Factory: Synthetic Organisms From This $1.4 Billion Startup Will Revolutionize Manufacturingfiercebiotech - Jun, 12 2019
Synlogic, Ginkgo expand synthetic biology research pactWall Streets Journal - May, 21 2019
Ginkgo Bioworks Takes to Acquisitions in Quest to Prove its Worthxconomy - May, 15 2019
Ginkgo Eyes Antibiotics With Deal for Warp Drive’s Gene “Mining” TechEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
